Jerusalem, Israel.

A new case report using the NovellusDx FACT® system was published in Journal of Thoracic Oncology, adding to the growing body of work utilizing the FACT system to annotate NGS data with its in-depth functional significance and drug response analysis.

The work, led by Dr. Nir Pelled from Davidoff Cancer Center, Rabin Medical Center, reports a case of a patient with multiple EGFR mutations which highlights tumor heterogeneity leading to a mixed response to osimertinib and emphasizes the complexity of EGFR driven lung cancer. Sub-clonal tumor evolution was proven by tissue biopsy and monitored via serial analyses of cell-free circulating tumor DNA (cfDNA) at disease progression and addressed using EGFR TKI combination therapy.